CDKN2A(p16) and CDKN1A(p21) status strongly correlated with each other (P=0.0038). Yet, only four cases were HPV positive by DNA in situ hybridization or by reverse transcriptase PCR E6/E7 mRNA ...

Oncotarget Volume 11, Issue 12 reported that the p16 tumor suppressor is coded by CDKN2A and plays an important role during carcinogenesis and tumor progression in numerous tumor entities.

These include CDKN2A, also called p16. These p16 mutation carriers have a 15% to 20% lifetime risk of developing pancreatic cancer. That is why they are offered surveillance. ...

The gene p16/CDKN2A is an important determinant of melanoma risk. A commercial test is presently available to assess the status of this locus. However, because of uncertainties regarding the ...

Since its discovery as a CDKI (cyclin-dependent kinase inhibitor) in 1993, the tumor suppressor p16 (INK4A/MTS-1/CDKN2A) has gained widespread importance in cancer. The frequent mutations and ...

All 26 patients tested negative for p16. The results showed a 12-week disease control rate (DCR) of 54%, and 16 of 20 (80%) evaluable patients had some degree of tumor reduction at 24 weeks.

Familial atypical mole melanoma: Two or more blood relatives with melanoma and an underlying CDKN2A/p16 mutation. Assocation with pancreatic cancer: OR 47.8, 95% CI 28.4–74.7. Prevalence: >1/1000.

However, CDKN2A mutations may indicate a poor prognosis later in the disease. To find the best way to use this new information to help patients in the clinic, more research is required.